R. Vollenhoven, R. Furie, Eric F Morand, K. Kalunian, M. Dall'Era, S. Goode-sellers, Puja Joshi, George Kong, Ting Wang, Xing Wei, Y. Lahoud, C. Barbey
{"title":"LP-184: litfilimab治疗成人活动性系统性红斑狼疮TOPAZ-1和TOPAZ-2两项3期、随机、双盲、安慰剂对照的疗效和安全性研究的基本原理和设计","authors":"R. Vollenhoven, R. Furie, Eric F Morand, K. Kalunian, M. Dall'Era, S. Goode-sellers, Puja Joshi, George Kong, Ting Wang, Xing Wei, Y. Lahoud, C. Barbey","doi":"10.1136/lupus-2023-kcr.259","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":359413,"journal":{"name":"E-Poster Presentation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2\",\"authors\":\"R. Vollenhoven, R. Furie, Eric F Morand, K. Kalunian, M. Dall'Era, S. Goode-sellers, Puja Joshi, George Kong, Ting Wang, Xing Wei, Y. Lahoud, C. Barbey\",\"doi\":\"10.1136/lupus-2023-kcr.259\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":359413,\"journal\":{\"name\":\"E-Poster Presentation\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"E-Poster Presentation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/lupus-2023-kcr.259\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"E-Poster Presentation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2023-kcr.259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2